Larry Allen, MD: Personalizing Current and Future Heart Failure Therapies

The field of heart failure (HF) therapy is nearly unrecognizable to that of almost one decade ago. Successive findings in cardiovascular safety and benefit from SGLT-2 inhibitor therapies—including for in-need patients with preserved ejection fraction (HFpEF)—was behind a boom in available complementary and leading therapies for HF. While the field is still growing, clinicians are in need of updated guidance on how all the newly availble—and possibly future—agents fit into their care plans.

Larry Allen, MD, Medical Director, Heart Failure, University of Colorado Anschutz School of Medicine, recently spoke on the individualized care plan for patients with heart failure at Beaumont Health's 30th Annual Cardiovascular Conference at Beaver Creek.

The leading clinician joined HCPLive Managing Editor Kevin Kunzmann for a 5-part extended discussion on individualizing heart failure treatment. Key topics included context on the pivotal trials supporting new drugs; prescribing strategies and navigating costs with patients; potential FDA approvals for new agents this year; needs in HFpEF treatment; and the latest organization guidelines for care.

Navigate the playlist above to listen to Allen's perspective on everything heart failure treatment.